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Embryonic development requires a complex program of events which are directed by a number of signaling molecules whose
expression must be rigorously regulated. We previously showed that expression of Fgf4, which plays an important role in
postimplantation development and growth and patterning of the limb, is regulated in EC cells by the synergistic interaction
of Sox2 and Oct-3 with the Fgf4 EC cell-specific enhancer. To verify whether this mechanism was also operating in vivo,
and to identify new elements controlling Fgf4 gene expression in distinct developmental stages, we have analyzed the
expression of LacZ reporter plasmids containing different fragments of the Fgf4 gene in transgenic mouse embryos. Utilizing
these transgenic constructs we have been able to recapitulate, for the most part, Fgf4 gene expression during embryonic
development. We show here that most of the cis-acting regulatory elements determining Fgf4 embryonic expression are
located in conserved regions within the 3* UTR of the gene. The EC cell-specific enhancer is required to drive gene
expression in the ICM of the blastocyst, and its activity requires the Sox and Oct–proteins binding sites. We were also able
to identify specific and distinct enhancer elements that govern postimplantation expression in the somitic myotomes and
the limb bud AER. The myotome-specific elements contain binding sites for bHLH myogenic regulatory factors, which
appear to be essential for myotome expression. Finally, we present evidence that the very restricted pattern of expression
of Fgf4 transcripts in the AER results from the combined action of positive and negative regulatory elements located 3* of
the Fgf4 coding sequences. Thus the Fgf4 gene relies on multiple and distinct regulatory elements to achieve stage- and
tissue-specific embryonic expression. © 1998 Academic Press
INTRODUCTION
Embryonic development involves a complex program of
events that must be executed in a precise and timely
fashion. Much of the coordination of these events is
achieved by the directive instructions of extracellular sig-
naling molecules that influence the expression of specific
gene subsets and ultimately determine the proliferative
state or identity of the target cell. Because these signaling
molecules have a profound effect on cell growth and differ-
entiation, it is imperative that their expression be rigor-
ously regulated. Thus, elucidation of the regulatory mecha-
nisms that govern differential expression of these signaling
molecules is fundamental to an understanding of the pro-
cess of development.
Members of the fibroblast growth factor (FGF) family
have been shown to influence a wide range of develop-
mental events (Basilico and Moscatelli, 1992; Goldfarb,
1996). A variety of experiments using gene knock-out and
transgenic technology, as well as evidence from human
genetics, has revealed that FGF signaling plays a major
role in many aspects of development, including postim-
plantation mouse development, gastrulation, midbrain
formation, myogenesis, growth and patterning of the
limb, and bone morphogenesis (Basilico and Moscatelli,
1992; Goldfarb, 1996).
An important role in development has been demon-
strated for FGF4. This growth factor is essential for
postimplantation mouse development, since embryos
homozygously null for the Fgf4 gene undergo uterine
implantation but do not develop substantially thereafter
(Feldman et al., 1995). In addition a number of elegant
experiments have shown that FGF4 is an essential com-
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ponent of the signaling network required for growth and
patterning of the developing limb (Goldfarb, 1996; John-
son and Tabin, 1997).
The pattern of expression of Fgf4 is highly specific, being
both spatially and temporally restricted to very discrete
embryonic tissues. Fgf4 transcripts are initially observed in
the preimplantation blastocyst at embryonic day 4.5 (E4.5)
within the inner cell mass (ICM). After implantation, the
level of expression gradually decreases, and, from gastrula-
tion onward, Fgf4 transcripts are detected in various tissues
at different stages, such as the primitive streak (E7.25), the
branchial arches and pharyngeal pouches (E9.0–9.5), the
somitic myotome (E9.5–11.5), the apical ectodermal ridge
(AER) of the developing limb bud (E10.5–11.5), and finally
the tooth bud (E14.5) (Niswander and Martin, 1992;
Drucker and Goldfarb, 1993). At later stages of develop-
ment, Fgf4 expression is no longer detected, remaining
silent in the adult. In tissue culture, the Fgf4 gene is only
expressed in undifferentiated murine and human embryo-
nal carcinoma (EC) cell lines as well as in embryonal stem
(ES) cells. Treatment of EC cells with retinoic acid, which
induces differentiation, results in shutoff of Fgf4 gene
expression (Velcich et al., 1989).
The regulation of Fgf4 expression is mostly transcrip-
tional. The major cis-element responsible for EC cell-
specific expression of both the human and murine genes is
a conserved DNA domain located in the 39 untranslated
region (UTR) of the third exon (Curatola and Basilico, 1990).
This element behaves as an EC cell-specific enhancer
whose activity depends on the interaction with two pro-
teins belonging to multigene families of transcriptional
regulators, Oct-3 and Sox2, both of which are specifically
expressed in EC and ES cells, as well as in the ICM of the
blastocyst. These factors bind cooperatively to adjacent
sites on the Fgf4 EC enhancer and synergistically activate
transcription (Dailey et al., 1994; Yuan et al., 1995; Ambro-
setti et al., 1997).
Both Oct-3 and Sox2 are expressed in the ICM of the
blastocyst (Rosner et al., 1990; Scholer et al., 1990; Col-
lignon et al., 1996; Avilion et al., 1998), consistent with the
prediction that the presence of both Sox2 and Oct-3 is
required for activation of the Fgf4 enhancer. However,
during later stages of development, Fgf4 expression occurs
at sites where combined expression of Sox2 and Oct-3 has
not been detected (Rosner et al., 1990; Scholer et al., 1990;
Uwanogho et al., 1995; Collignon et al., 1996; Kamachi et
al., 1995; Scholer, 1991; Niswander and Martin, 1992).
These observations suggested that, while Fgf4 gene expres-
sion in the ICM was likely dependent on the interaction of
the EC cell-specific enhancer with Sox2 and Oct-3, expres-
sion of this gene at later developmental stages was accom-
plished by distinct regulatory elements.
To verify these hypotheses, and to identify new elements
controlling expression of the Fgf4 gene in distinct develop-
mental stages, we have analyzed the expression of LacZ
reporter plasmids containing different Fgf4 DNA segments
in transgenic mice. In this report, we show that most Fgf4
cis-regulatory elements operating in vivo are located in the
39 UTR of the gene. We show that the Sox/Oct binding sites
located in the Fgf4 EC cell-specific enhancer are essential
for expression of the gene in the preimplantation ICM, and
were also able to define distinct enhancer elements that
drive expression in the somitic myotomes and the AER.
Finally, we present evidence that the very restricted pattern
of expression of Fgf4 in the posterior half of the AER is the
result of the combined action of positive- and negative-
acting elements situated downstream of the Fgf4 coding
sequences.
MATERIALS AND METHODS
LacZ Reporter Constructs
The pGNA LacZ vector was used in transgenic constructs.
pGNA is identical to pGN (Le Mouellic et al., 1990) except that it
contains an additional SV40 polyadenylation signal downstream of
the Neo cassette. In the murine Fgf4 genomic sequences, nucleo-
tide 1 corresponds to an EcoRI site located 3823 and 5257 nt
upstream of the ATG initiation codon and the TGA termination
codon of the murine Fgf4 gene, respectively. A 1380-bp Fgf4
promoter-containing fragment (Fgf4 59 region, nt 2313–3693) and a
809-bp Fgf4 fragment containing the Fgf4 donor and acceptor
splicing sites (Fgf4 fragment, nt 4308–5117) were inserted up-
stream of the LacZ gene. The various Fgf4 39 fragments were
inserted downstream of the LacZ gene and the SV40 poly(A) site.
To make constructs 1 and 7 a 5.0-kb Fgf4 fragment (nt 5259 to ca.
10,300) containing the entire 39 UTR (nt 5259–7559) was inserted
in the forward orientation. Construct 1 was excised from the vector
using SphI and SalI, while construct 7 was excised with ApaI. To
make constructs 2, 9, and 4, a 1595-bp Fgf4 fragment (nt 5870–
7465) was PCR-amplified, and inserted in the reverse orientation.
Construct 2 was excised from the vector using SphI and SpeI, while
construct 9 was excised using SphI and BsmI (nt 6570). In addition
to the 1595-bp fragment, a 2072-bp Fgf4 fragment (nt 245–2317) was
inserted 59 to the Fgf4 59 region to produce construct 4, which was
excised with ApaI and SpeI. To make construct 3, a 638-bp Fgf4
fragment (nt 6827–7465) was PCR-amplified and inserted in the
forward orientation. To make construct 8, a 335-bp Fgf4 fragment
(nt 6262–6597) was PCR-amplified and inserted in the forward
orientation. Three 39 Fgf4 mutated fragments were generated by
means of sequential PCR amplification (Ausubel et al., 1994). The
primers were designed to produce nucleotide substitutions or
deletions. Construct 5 contains a 1438-bp Fgf4 fragment (nt 5599–
7037) that carries a deletion corresponding to the Sox/Oct binding
sites (nt 6704–6727). Construct 6 contains a 1761-bp Fgf4 fragment
(nt 5704–7465) that carries a deletion corresponding to most of the
Hom3a region (nt 6281–6578). Construct 10 contains a 335-bp Fgf4
fragment (nt 6262–6597) that carries G to A substitutions in the
two E boxes (nt 6267 and 6362).
Generation of Transgenic Mice
All the constructs were linearized using the appropriate restric-
tion enzymes, agarose gel-purified, electroeluted, concentrated
with Elutip-D minicolumns (S&S), and resuspended in bidistilled
water at a concentration of 100–300 mg/ml. Standard microinjec-
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tion of DNA into the pronucleus of fertilized eggs was achieved at
the NYU Transgenic Mouse Facility. Swiss Webster mice were
used.
Testing of Transgenic DNA Carriers
Incorporation of the transgene into the embryos was tested on
tail DNA (for established transgenic lines, constructs 1 through 6)
or on yolk sac DNA of E11.5 embryos (for transient transgenics,
constructs 7 through 10). Genomic DNA was extracted from tails
or yolk sack by treatment with 0.4 mg/ml proteinase K (Gibco BRL)
at 55°C, debris precipitation with 6 M NaCl, and DNA precipita-
tion with 2-propanol. DNA was digested with EcoRI, BamHI, or
HindIII and run on agarose gels for Southern blot hybridization. A
3.8-kb EcoRI/EcoRI probe containing Fgf4 and lacZ sequences was
used. Alternatively, the entire fragments derived from constructs 1,
2, and 3 were used as probes. The percentage of transgenics ranged
between 10 and 25%. At least two founders per construct were bred
with wild-type animals, and at different days of gestation, the
progeny from F1 or in some cases F2 was sacrificed for X-gal
staining.
Analysis of Transgene Expression
b-Gal activity was analyzed in whole-mount embryos by stan-
dard X-gal staining. Embryos were removed from the uterus, rinsed
in 0.1 M phosphate buffer (pH 7.3), fixed with 0.2% glutaraldehyde
in phosphate buffer containing 5 mM EGTA and 2 mM MgCl2 for
20 min at room temperature, washed in phosphate buffer contain-
ing 0.02% Nonidet P-40 and 2 mM MgCl2 (wash buffer) three times
for 15 min at room temperature, and stained with X-gal (1 mg/ml)
in wash buffer containing 5 mM potassium ferricyanide and 5 mM
potassium ferrocyanide overnight at 37°C. In the case of the
transgenic lines, at least 30 embryos per line were analyzed for
transgene expression. Around 50% of the litter, as statistically
predicted, was positive for X-gal staining. In the case of transient
transgenics, between 30 and 50 embryos per construct were ana-
lyzed for transgene expression at each stage. A minimum of 3
positive embryos for each construct was examined, while lack of
b-gal expression was verified in at least 30 embryos. Photographs
were taken with a camera attached to a dissecting microscope
(Leica).
Blastocyst Flushing and Culturing
E3.5 blastocysts were flushed from the uterus and cultured over
a layer of mitomycin C (Sigma) -treated mouse embryonic fibro-
blasts (feeder cells) under nondifferentiating conditions in 3.5-cm
dishes for 2–3 days (DMEM, murine LIF 103 U/ml) (Joyner, 1993).
After fixation with 2% formaldehyde and 0.2% glutaraldehyde in
PBS, the blastocysts were stained with X-gal. Pictures were taken
with a camera attached to an inverted microscope (Zeiss).
Cryosections
E11.5 stained embryos carrying transgene 2 were refixed in 4%
paraformaldehyde overnight at 4°C, washed with PBS, and infused
in 30% sucrose in PBS until sinking. Upon quick-freezing and
mounting with OCT compound, 12 mM coronal and parasagittal
cryosections at the trunk level were performed. Sections were
mounted on microscope slides, warmed at 37°C for 2 h, refixed, and
slightly counterstained with hematoxylin and eosin Y.
Cell Culture and Transfections
Cell culturing of undifferentiated F9 and HeLa cells was per-
formed as described elsewhere (Dailey et al., 1994). CaPO4 trans-
fections, performed essentially as described in Curatola and Ba-
silico (1990), utilized 5 mg of reporter plasmid in a total of 25 mg of
mouse genomic DNA. b-Galactosidase assay of cell extracts or
X-gal staining of fixed cells was performed 30 h after transfection.
In Situ Hybridization
Whole-mount embryos derived from a cross between a wild-type
C57B/6 3CBA female and a male transgenic for construct 2 were
dissected at E10.5 and E11.5 and processed as described by Hen-
rique et al. (1995). Embryos were treated with proteinase K (2
mg/ml) for 59 at 37°C. For hybridization, two digoxigenin-labeled
antisense RNA probes were used together. The first probe corre-
sponds to a 410-nt DNA fragment including the first exon of the
Fgf4 gene. The second probe corresponds to a 400-nt DNA fragment
which includes the Hom2 region of the 39 UTR. None of these
fragments is contained in transgenic construct 2 (Fig. 2A).
RESULTS
To identify the cis DNA elements governing Fgf4 gene
expression during embryonic development, we constructed
a series of plasmids designed to express the bacterial LacZ
gene under the control of Fgf4 regulatory elements and used
them to produce transgenic mice lines or in “transient”
transgenesis experiments. The basic construct (Fig. 1A)
consists of approximately 1200 bp of the 59 region of the
murine Fgf4 gene including the promoter, a 39 portion of the
first intron, the entire second exon and intron, and a few
nucleotides of the third exon followed by the LacZ gene. At
39 of the LacZ gene we inserted fragments of variable length
derived from the 39 UTR of the Fgf4 gene (see also Fig. 2).
We focused our analysis on the 39 UTR because: (a) the Fgf4
EC cell-specific enhancer maps there and (b) the 39 UTR of
the third exon contains three well-defined regions of se-
quence conservation between the human and murine Fgf4
genes (Curatola and Basilico, 1990). The first region (Hom1)
is a short AT-rich stretch just downstream of the TGA
translation terminator, and might play a role in RNA
stability. The second region (Hom2) encompasses about 150
bp, and the third (Hom3) is over 500 bp long and was divided
into Hom3a and Hom3b. Hom3b contains the EC cell
enhancer (Curatola and Basilico, 1990; Dailey et al., 1994).
The remarkable degree of conservation in these noncoding
DNA sequences suggested to us that the major Fgf4 DNA
regulatory elements could be located in the 39 UTR.
We first tested expression of these constructs in F9 EC and
HeLa cells. As expected, F9 cells transfected with constructs
containing the EC cell enhancer were able to express the
reporter LacZ gene, as assessed by cell staining with X-gal, by
the b-galactosidase assay of cell extracts, Western blot of cell
extracts using a b-gal antibody, and by Northern blot of
poly(A)1 RNA using a LacZ probe (data not shown). In
contrast, constructs harboring only nonconserved fragments
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of the 39 UTR or lacking any UTR sequence (not shown) had
essentially no activity. None of these constructs were able to
produce b-gal activity in HeLa cells (data not shown).
We generated transgenic mice by microinjecting the linear-
ized constructs into fertilized mouse eggs. Southern blot
analysis of the tail tips from F0 mice showed that in all cases
examined the transgene was tandemly integrated into the
genome in a number of copies that varied from founder to
founder (Fig. 1). Digestion with BamHI of the DNA from one
of the founder mice harboring transgene 1 (Fig. 1A) probed
with an EcoRI probe containing the entire LacZ region and
upstream Fgf4 sequences produced two strong bands of 4.2 and
3.5 kb (Fig. 1B). The sum of the molecular weights of these two
bands (7.7 kb) corresponds to the full length of the injected
fragment from transgene 1. Similarly, digestion with EcoRI
and hybridization with an SphI/SalI probe spanning the entire
plasmid produced three major bands of 3.8, 2.5, and 1.4 kb.
Again the total length of these bands corresponds to the entire
length of the injected DNA fragment. Similar results were
obtained with other transgenic mice (not shown).
These results indicate that the transgenic loci contain
tandemly arranged repeats of the entire DNA fragment
injected, resulting in placement of the 39 UTR sequences
both 59 and 39 of the Fgf4 promoter. Thus we cannot
conclude that the location of the regulatory Fgf4 elements
downstream of the LacZ gene in our plasmid constructs
plays a role in the pattern of expression we observed. No
correlation between copy number of the transgene and level
of expression of LacZ was observed.
The ICM, Myotomes, and AER cis-Acting
Regulatory Elements Are Contained within the 3*
UTR of the Fgf4 Gene
Two LacZ constructs containing either the entire Fgf4 39
UTR (construct 1) or a nonconserved 39 fragment of the
FIG. 1. The transgene is inserted in tandem. (A) Schematic representation of the basic construct used for generating transgenic mice. The
lacZ reporter gene was placed under the control of the murine Fgf4 59 region (nt 2443–3693), a gene fragment (nt 4308–5117) which contains
a portion of the first intron, the second exon, the second intron, and a few nucleotides of the third exon, and the 39 untranslated region (39
UTR) (nt. 5259–7433) as described in the text and under Materials and Methods. The 39 UTR was placed downstream of the SV40 poly(A).
The three regions of homology between mouse and human sequences are shown in black rectangles (Hom1 5310–5434, Hom2 5705–5857,
Hom3 6260–6822). Hom3 was divided into 3a (nt 6260–6597) and 3b (nt 6597–6822). The lacZ gene and the SV40 poly(A) sequences are
from the pGNA vector and are not drawn to scale. The numbering in the Fgf4 fragments is relative to an EcoRI site (nt 1) located 3823 and
5257 nt upstream of the ATG initiation and the TGA termination codons of the murine Fgf4 gene, respectively. Cleavage sites for EcoRI
and BamHI are indicated below. (B) Southern blot analysis of DNA from the tail tip of a transgenic mouse. Genomic DNA was purified as
described under Materials and Methods and digested with BamHI or EcoRI. The probe used for detection in the BamHI digestion was the
32p-labeled 3.8 kb EcoRI/EcoRI fragment, while in the case of EcoRI digestion the entire 7.7-kb SphI/SalI fragment was used. * indicates
the detection of a Fgf4 endogenous gene fragment. In all cases the signals derived from the transgene fragments are more intense than the
signals derived from the Fgf4 endogenous gene fragments, indicating that the transgene copy number is greater than 1.
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UTR (construct 3, Fig. 2A) were first analyzed for expres-
sion in transgenic mice. Two independent lines of trans-
genic animals were studied for each construct. Embryos
produced by crossing F0 or F1 transgenic male mice with
wild-type females were sacrificed at various stages of devel-
opment and analyzed for b-gal expression using X-gal stain-
ing as described under Materials and Methods. Construct 1
was strongly expressed in the ICM of the blastocyst,
somitic myotomes, and the limb bud AER (Fig. 3) in both
transgenic lines. In contrast, construct 3 was not expressed
at any stage or in any tissue, in both transgenic lines
examined (Fig. 3). These results support the hypothesis that
the conserved portions of the 39 UTR contain most of the
Fgf4 cis-regulatory elements, and that the Fgf4 promoter per
se has little activity.
In both myotomes and the AER, the staining observed
with either construct 1 or 2 transgenics (Fig. 2A) was first
weakly detected at E10.5, peaked at E11.5 (Fig. 4), and was
rapidly lost from E12.5 on (not shown). Thus there seems to
be a slight delay in the time of onset of b-gal expression if
compared to the times at which Fgf4 transcripts are ob-
served (Niswander and Martin, 1992; Drucker and Goldfarb,
1993). This could be due to the time needed to accumulate
sufficient b-gal protein for easy detection of the activity, or
perhaps also to slight variations in the staging of the
embryos. It should also be noted that Fgf4 transcripts
exhibit a restricted pattern of expression localized only to
the posterior portion of the limb bud AER (Niswander and
Martin, 1992). However, in mice transgenic for construct 1
(and also others, see below), the b-gal expression appeared
to be much broader since not only the posterior but also the
anterior region of the AER was clearly stained (Fig. 3).
Although in situ analysis of Fgf4 transcripts has detected
expression in the primitive streak, branchial arches, and
FIG. 2. Schematic representation of the constructs used to generate transgenic mice and of b-gal expression in the ICM, myotomes, and
AER obtained with each construct. (A) Ten constructs were generated as described under Materials and Methods. The conserved regions
of the Fgf4 39 UTR (black boxes) that are contained in the constructs are indicated (see also Fig. 1). Additional 59 and 39 fragments that are
contained in constructs 4 and 7, respectively, are also indicated. Construct 5 contains a 24-bp deletion of the Sox/Oct binding sites located
within Hom3b. Construct 10 is identical to construct 8 with the exception that the E-boxes have been mutated by performing G to A
substitutions. It should be noted that the portions of the 39 UTR contained within constructs 2, 4, and 9 were inserted in the reverse
orientation of what is shown. (B) b-Gal expression obtained with each construct in the inner cell mass (ICM), the myotomes (neck and
trunk/tail), and the limb bud apical ectodermal ridge (AER). Construct 7 expresses b-gal only in the posterior region of the AER (p). 11,
high levels of expression; 1, low levels; 2, undetectable. ND, not determined. Constructs 1 through 7 do not express b-gal in the primitive
streak. Constructs 8, 9, and 10 have not been analyzed in the primitive streak. Two independent transgenic lines were established for each
construct 1 through 6. Transgenic founders or F1 mice were crossed with wild-type mice and their progeny was analyzed for b-gal
expression. The pattern of b-gal expression shown in B was consistent in lines transgenic for the same construct. At least 30 embryos from
each transgenic line were examined at each stage as described in the text. For constructs 7–10, transgenic F0 conceptuses were analyzed
at various developmental stages following zygote microinjection. Between 30 and 50 embryos per construct were analyzed for b-gal
expression at each stage. The presence of the transgene was tested on yolk sac DNA of E11.5 embryos. The percentage of transgenic
embryos ranged between 10 and 25%.
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pharyngeal pouches (Niswander and Martin, 1992; Drucker
and Goldfarb, 1993), surprisingly none of the LacZ con-
structs analyzed were able to express b-gal in these tissues.
This was true also for construct 4, which is identical to 2
but contains an additional 2.0-kb fragment upstream of the
promoter, and construct 7 which contains an additional 2.4
kb of sequences downstream of the 39 UTR (Fig. 2). Thus,
the cis-acting DNA elements responsible for Fgf4 expres-
sion in these tissues are likely to be localized outside the
fragments included in our studies (ca. 10 kb). Expression in
the tooth bud was detected in mice transgenic for construct
1, but we did not pursue this observation further (data not
shown).
Thus, we were able to recapitulate Fgf4 expression at
FIG. 5. Transgene expression is limited to the myotomes and is absent in the dermatome and sclerotome layers. Coronal cryosection at
the trunk level, of an E11.5 embryo transgenic for construct 2 (A) showing specific X-gal staining in both the dorsomedial (DM) and
ventrolateral (VL) domains of the myotomes. Trunk-level parasagittal cryosection of an E11.5 transgenic embryo (B) showing specific X-gal
staining in the myotomes (Myo). In contrast, the neighboring mesodermal layers dermatomes (Derm) and sclerotomes (Scl) do not express
the transgene. NT, neural tube. Magnification: 653 (A) and 1303 (B).
FIG. 6. Expression in the myotomes is governed by Hom3a and Hom2. X-gal staining of an E11.5 embryo carrying construct 8 (Fig. 2) is
observed in the trunk (tr) and tail (ta) myotomes, but not in the neck (ne) myotomes (A). X-gal staining of an E11.5 embryo carrying
construct 6 (Fig. 2) is observed in the neck myotomes, but not in the trunk or tail myotomes (B).
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least in three tissues by utilizing the Fgf4 39 UTR: in the
ICM of the preimplantation blastocyst, and later in
development in the myotomes and AER. Furthermore, as
discussed above, the temporally restricted pattern of
expression of the Fgf4 gene was conserved in all trans-
genic embryos (Fig. 4). FGF4 is not expressed in
mouse fibroblasts. In line with this finding, cultures of
embryonic fibroblasts obtained from transgenic mice at
E16.5 showed no detectable b-gal expression (data not
shown).
Expression in the Inner Cell Mass Is Governed by
Hom3b
The Fgf4 EC cell-specific enhancer, which corresponds to
the Hom3b region of the 39 UTR, is activated by the
synergistic action of two transcriptional regulators, Sox2
and Oct-3, which cooperatively bind to adjacent sites on the
enhancer DNA (Yuan et al., 1995; Ambrosetti et al., 1997).
Since EC cells resemble the ICM of the blastocyst (Martin,
1980), and both Oct-3 and Sox2 are expressed in this tissue,
we predicted that the same elements were responsible for
Fgf4 expression in the ICM in vivo. To test this hypothesis
a number of constructs (depicted in Fig. 2A) containing
different fragments of the Fgf4 39 UTR were tested for their
ability to express b-gal in the ICM of transgenic mice.
Because of the experimental difficulty of flushing
“hatched” blastocysts at E4.5, we flushed E3.5 blastocysts
and cultured them for 2–3 days under nondifferentiating
conditions. During this time, the blastocysts emerge from
the zona pellucida and adhere to the underlying layer of
feeder cells. This is reminiscent of what occurs during the
uterine implantation process. Shortly after the blastocysts
are immobilized, they are subjected to X-gal staining. Under
these conditions, all constructs harboring the Hom3b re-
gion (1, 2, 4, 6, 9) were able to drive b-gal expression in the
ICM of the cultured blastocysts, while constructs 3 and 8,
which do not contain the Hom3b region, were not (Fig. 2).
The validation of the prediction that the ICM enhancer
element corresponds to Hom3b was provided by the analy-
sis performed with constructs 9 and 5. Construct 9 contains
only the Hom3b region plus nonconserved 39 sequences,
which have no activity per se (construct 3, Figs. 2 and 3),
and can express b-gal in the ICM (Fig. 2). The mutated
construct 5, which lacks a specific 24-bp segment that
corresponds to the Sox/Oct binding sites, failed to drive
b-gal activity in the ICM. Thus the Hom3b region, corre-
sponding to the previously identified EC-cell enhancer, is
necessary to drive gene expression in the ICM and its
activity requires interaction with Sox2 and Oct-3.
Expression in the Myotomes Requires Hom3a and
Hom2
In embryos transgenic for either construct 1 or 2 (Fig.
2A), b-gal was expressed at E10.5–11.5 in both the dorso-
medial (DM) and ventrolateral (VL) domains of neck and
trunk myotomes, as well as in the tail myotomes. The
staining in the neck and trunk myotomes initially ap-
pears in the DM domain, then becomes more intense and
reaches the VL domain as well. Coronal and parasagittal
cryosections from E11.5 transgenic embryos performed at
the trunk level revealed specific X-gal staining only in
the myotome layer, in both DM and VL domains, while
the neighboring layers of the dermatome and sclerotome
were negative (Fig. 5).
To identify the elements involved in myotome expres-
sion, a variety of constructs containing different portions of
the 39 UTR were tested for their ability to drive b-gal
expression in the myotomes of transgenic embryos at
E10.5–12.5 (Fig. 2). Construct 2, which contains only the
Hom3 region, gave the same pattern of expression of con-
struct 1, but expression in the rostral myotomes was
weaker. The same was true for construct 4, which contains
additional Fgf4 59 sequences. Construct 9, which contains
only the Hom3b region, had no detectable myotome expres-
sion, suggesting that the myotome-specific elements en-
compassed the Hom2 and Hom3a regions, and possibly the
intervening sequences. This hypothesis was confirmed us-
ing construct 8, which contains only the Hom3a region.
Embryos transgenic for this construct exhibited b-gal ex-
pression in the trunk and tail myotomes, but not in the
neck myotomes (Figs. 2 and 6). On the other hand construct
6, which contains the Hom2 and 3b regions, had weak but
detectable expression in the rostral myotomes, and no
expression in trunk and tail myotomes (Fig. 6). These
results support the notion that Fgf4 expression in the neck
myotomes is controlled by a different mechanism than that
of the trunk and tail myotomes.
The pattern of myotome expression was not altered when
the mutant construct 5 that lacks the Sox/Oct binding sites
in the Hom3b region was utilized, showing that the binding
of members of these transcription factor families to the EC
cell Fgf4 enhancer is dispensable for gene expression in the
myotomes. The addition of further 59 sequences (4 vs 2) or
further 39 sequences (7 vs 1) does not appear to provide any
new DNA elements relevant to expression in the myo-
tomes. Likewise, by comparing construct 1 vs 5 the Hom1
region appears to be dispensable for controlling gene expres-
sion in these tissues (Fig. 2).
Taken together, these data define the existence of
cis-acting element(s) located within Hom3a, that are
required for directing gene expression in the myotomes,
and are by themselves sufficient to activate gene expres-
sion in the trunk and tail myotomes (Fig. 6). In addition
to these enhancer elements, other elements, which in-
clude the Hom2 region and possibly sequences comprised
between Hom2 and Hom3a, are required for fully activat-
ing the expression of the transgene throughout the neck
myotomes. These additional elements do not appear to
have strong enhancing activity per se, but probably act in
conjunction with the elements located in Hom3a (Fig. 2).
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Expression in the AER Is Governed by Activating
(Hom3a) and Inhibiting (3* Region) Elements
The Fgf4 regulatory elements driving gene expression on
the AER of the limb bud also appear to map in the Hom3a
region. All constructs containing this 330 bp DNA frag-
ment (1, 2, 4, 5, 7, and 8) expressed b-gal in the AER,
whereas constructs 6 and 9, which do not contain an intact
Hom3a region, were unable to drive b-gal expression in this
structure (Fig. 2). The Hom1, Hom2, and Hom3b regions do
not appear to play a role.
However, the pattern of expression of all of the constructs
that share the Hom3a elements did not precisely recapitu-
late the normal distribution of Fgf4 transcripts in the AER,
which has been reported to be restricted to the posterior
AER (Niswander and Martin, 1992). This appeared to be
true also in our transgenic embryos that, using in situ
hybridization, showed detectable expression of Fgf4 RNA
only in the posterior approximately 2
3
of the AER (Figs. 7C
and 7D). On the other hand, as mentioned above, b-gal
expression in most of our transgenic embryos was signifi-
cantly broader and covered the entire AER (Figs. 3 and 7).
Interestingly, the AER expression obtained with construct 7
was very restricted and limited to a portion of the posterior
AER (Fig. 7B). This construct is identical to construct 1, but
contains an additional 2.4 kb of 39 sequences. These results
suggest that the lack of Fgf4 expression in the anterior
portion of the AER may be due to the presence of inhibitory
factors, and that these factors may interact with the DNA
elements contained in the additional 39 sequences present
in construct 7. Therefore, the pattern of Fgf4 transcripts
observed in the AER by in situ hybridization may result
from “activating” factors, present throughout the AER, that
interact with elements within Hom3a as well as from
“repressing” factors within the anterior AER interacting
with sequences within the 2.4-kb 39 region.
The AER Elements Overlap Myotome-Specific
Elements, but Are Distinct
From the analysis described above, it appeared that both
AER and caudal myotome-specific regulatory elements
mapped in the Hom3a region. We noticed that the Hom3a
region contains two E-boxes, which could represent binding
sites for bHLH factors such as MyoD, myf-5, myf-6 (MRF4),
and myogenin, known to play a role in muscle-specific
expression (Buckingham, 1992; Weintraub, 1993; Molken-
tin and Olson, 1996; Cossu et al., 1996). In an attempt to
distinguish the myotomes from the AER-specific elements
we produced a variant of construct 8, in which the two
E-boxes were altered by site-directed mutagenesis. This
construct was injected into fertilized eggs in a number of
“transient” transgenesis experiments and the embryos were
sacrificed at day E11.5. None of the five transgenic embryos
obtained showed b-gal expression in the myotomes, al-
though they showed expression in the AER and a variable
degree of ectopic expression (Fig. 8). While further analysis
will be required to precisely identify the myotome-specific
elements, these results indicate that the myotome and
AER-specific elements, although overlapping, are likely to
be distinct, and that binding of bHLH-like transcription
factors to one or more of the E-boxes contained in the
Hom3a region is essential to drive Fgf4 gene expression in
the trunk/tail somitic myotomes.
DISCUSSION
The Fgf4 gene plays an important role in embryonic
development. Its expression in the ICM of the blastocyst
has been shown to be necessary for postimplantation mouse
development, and in the AER Fgf4 is part of a complex
network of signals which is necessary for growth and
patterning of the limb (reviewed in Goldfarb, 1996). Fgf4
expression is also likely to be important in other develop-
mental stages. For example, Fgf4 is not expressed in the
myotomes of myf-5 knock-out mice, which do not form the
distal portion of the ribs and have delayed muscle differen-
tiation (Braun et al., 1992; Grass et al., 1996), suggesting
that it could play a role in these processes. However, the
precise role of FGF4 in these and other developmental
events has not been clearly defined because of the early
lethality of Fgf4 knock-out embryos (Feldman et al., 1995).
Given its importance in development, and because this
gene is expressed in such a specific and restricted manner,
we initiated a study of the cis- and trans-acting elements
governing Fgf4 expression during embryogenesis.
Using mice transgenic for plasmid constructs expressing
the b-gal protein under the control of the Fgf4 promoter and
39 regulatory DNA elements, we were able to recapitulate,
at least in part, the specific pattern of expression of Fgf4 in
the embryo and to identify new regulatory DNA elements
which appear to direct Fgf4 gene expression in the somitic
myotomes and the AER of the limb bud. The major ele-
ments identified so far all map within the 39 noncoding
region of the Fgf4 gene, and the Fgf4 promoter per se has
little activity.
Expression in the ICM
Our previous work on the Fgf4 EC cell enhancer led to the
hypothesis that since this enhancer was specific for undif-
ferentiated EC cells, it was likely to be the major element
determining Fgf4 gene expression at this developmental
stage. This hypothesis was confirmed by the experiments
presented here. All constructs containing the Hom3b region
(the EC cell-specific enhancer) were able to drive b-gal
expression in the ICM, while constructs in which this DNA
element was absent were not. Furthermore, a deletion of
the Sox/Oct binding sites within the EC cell enhancer in
the context of a transgene containing most of the 39 UTR
resulted in lack of expression in the ICM. Thus the EC cell
enhancer is the major regulatory element of Fgf4 gene
expression in the ICM and Sox2 and Oct-3 are the main
transcription factors involved.
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FIG. 7. Expression in the AER is regulated by activating (Hom3a) and inhibiting (39 region) elements. (A) X-gal staining in the forelimb bud
(fLB) AER of an E11.5 embryo carrying construct 8 (Fig. 2). The pattern of expression runs both the anterior (a) and posterior (p) regions. (B)
X-gal staining in the forelimb bud (fLB) AER of an E11.5 embryo carrying construct 7 (Fig. 2). The pattern of expression is restricted to the
most posterior (p) region of the AER. (C and D) Whole-mount in situ hybridization of E10.5 embryos transgenic for construct 2 performed
using antisense digoxigenin-labeled riboprobes which recognize the endogenous Fgf4 RNA but not the RNA transcribed from the transgene,
as described under Materials and Methods. C and D show anterior or posterior views of the forelimb bud, respectively. Detectable staining
is only observed in the posterior portion of the AER. E11.5 embryos showed weaker, but similarly localized staining.
FIG. 8. Expression in the myotomes is abolished by mutating the E-boxes present in Hom3a. X-gal staining of an E11.5 embryo transgenic
for construct 10 (Fig. 2). Staining is observed in the AER but not in the myotomes. Compare with Fig. 6A. The staining detected in the
head/upper trunk was not observed in other transgenic embryos, and thus it probably results from ectopic expression.
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This conclusion is further supported by the results re-
cently obtained by Lovell-Badge’s group on Sox2 knock-out
mice (Avilion et al., 1998). These mice showed early em-
bryonic lethality, strikingly similar to that exhibited by the
Fgf4 knock-outs, and did not express Fgf4 RNA in their
blastocysts.
Expression in the Myotomes
The role that Fgf4 plays in the somitic myotomes is
unknown at the moment. FGF signaling is known to inhibit
the differentiation of myoblasts into myotubes (Basilico and
Moscatelli, 1992; Goldfarb, 1996) and thus FGF4 could act
as a growth factor for muscle precursor cells. It is also
possible that the major role of FGF4 in these structures is
paracrine, as suggested by the analysis of myf-5 knock-out
mice (Grass et al., 1996). Mice deficient for this myogenic
factor have only a delay in muscle formation, probably
because of compensation by MyoD, since mice doubly
deficient for Myf-5 and MyoD do not develop muscle
(Rudnicki et al., 1993). Interestingly, however, myf-5 mu-
tant mice fail to form major parts of the ribs and do not
express FGF4 or FGF6 in their somitic myotomes (Grass et
al., 1996). Since Fgf6 null mice have only a defect in adult
muscle regeneration (Floss et al., 1997), it is possible that
the most important signaling molecule affected by the
myf-5 knock-out is FGF4 and that this factor plays a role in
rib chondrocytes development, or that FGF4 and FGF6
perform a redundant function.
We have identified two myotome-specific elements map-
ping to the Hom2 and Hom3a regions of the Fgf4 gene.
While the Hom3a elements appear to be essential for
expression in the trunk and tail myotomes, the Hom2
region probably provides specific elements which are nec-
essary for rostral myotome expression, but need to act in
concert with Hom3a. The Hom3a element contains two
E-boxes, elements known to be able to bind factors of the
bHLH family, which include the myogenic factors myf-5
and MyoD (Buckingham, 1992; Weintraub, 1993; Molken-
tin and Olson, 1996; Cossu et al., 1996). The sequence of
the second E-box (CAGCTG) is perfectly conserved in the
human, murine, and chicken Fgf4 genes (unpublished data)
and mutation of both E-boxes suppressed transgenic b-gal
expression in the myotomes. Thus it is likely that one or
more of the myogenic bHLH factors is involved in Fgf4
myotome expression. Genetic evidence from the myf-5 null
mice (Grass et al., 1996) would suggest that myf-5 is an
essential activator of Fgf4 gene expression in the somites.
On the other hand, MyoD expression initiates in the
embryo at approximately the same time when we detect
b-gal transgenic expression (Cossu et al., 1996), but such
temporal arguments may be misleading. It is possible that
both myf-5 and MyoD may be able to function as activators
of Fgf4 gene expression. Myf-6 (MRF4) could also function
as a regulator of Fgf4 gene expression (Zhang et al., 1995).
Expression in the AER
Fgf4 RNA is expressed in the posterior AER and appears
to be an important component of a signaling network which
connects the AER and the limb bud mesenchyme and
eventually results in limb growth and patterning (Niswan-
der et al., 1993; Cohn et al., 1995; Goldfarb, 1996; Johnson
and Tabin, 1997). The first FGF expressed in the AER is
FGF8, which may be involved in inducing the expression of
sonic hedgehog (SHH) in the bud mesenchyme (Crossley et
al., 1996). SHH induces Fgf4 expression in the AER and
evidence has been presented indicating that FGF4 signals
are required to maintain SHH expression (Laufer et al.,
1994; Niswander et al., 1994; Johnson and Tabin, 1997).
Although a number of data suggest that Fgf8 expression is
essential for early bud formation (Vogel et al., 1996; Cross-
ley et al., 1996; Goldfarb, 1996), analysis of limb deformity
(ld) mouse mutants indicates that Fgf4 expression is also
important for proper limb development (Chan et al., 1995).
Homozygous ld mutants show shortened and malformed
limbs, and their AER are poorly organized. While expres-
sion of FGF8 is maintained in the ld mutants AER, FGF4 is
not expressed. In addition, ld embryos show a decrease in
the expression of SHH in the limb mesenchyme. Thus the
limb defect of ld mutants may be due to the absence of the
proliferative function of FGF4, combined with the reduc-
tion in SHH expression caused by FGF4 deficiency. BMP-2
is expressed in the posterior bud mesenchyme and in the
AER and may also participate in the regulation of Fgf4
expression (Niswander and Martin, 1993; Duprez et al.,
1996).
We have mapped the major Fgf4 regulatory DNA ele-
ments driving AER expression to the Hom3a region of the
39 UTR. These elements overlap with the myotome-specific
elements, but are likely to be distinct, since mutation of the
E-boxes contained in Hom3a abolishes expression in the
myotomes, but not in the AER. This conclusion is also
consistent with the findings of Grass et al. (1996) who
reported that Fgf4 expression is impaired in the myotomes
of myf-5 null mice, but is maintained in the AER. Similarly,
expression of Fgf4 RNA is maintained in the myotomes of
ld mice (Chan et al., 1995). The products of the ld locus,
formins, could obviously be important for Fgf4 expression
in the AER. Furthermore, since Fgf4 expression in the AER
has been shown to be dependent on SHH expression (Laufer
et al., 1994; Johnson and Tabin, 1997), the AER elements
are likely to be the target of transcription factors induced or
activated by SHH signaling.
Most of our transgenic constructs drive b-gal expression
throughout the AER, differently from the pattern of expres-
sion of endogenous Fgf4 RNA which is restricted to the
posterior part of the AER (Niswander and Martin, 1992).
Using whole-mount in situ hybridization we have con-
firmed the restricted pattern of expression of endogenous
Fgf4 transcripts, and thus it is of considerable interest that
the expression of construct 7, which contains an additional
;2 kb of 39 sequences, is very restricted and limited to the
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most posterior part of the AER (Figs. 2 and 7). This obser-
vation suggests that the 39 sequences are a target for factors
which act as inhibitors of gene expression. Such factors
could serve to spatially limit Fgf4 expression in the AER,
suggesting that its restricted expression results from posi-
tive (which direct expression throughout the entire AER)
and negative (which limit it to the posterior region) ele-
ments. The positive elements directing Fgf4 expression in
the AER could be similar to those influencing expression of
Fgf8 and msx-2 which are expressed throughout the AER
(Vogel et al., 1996; Sumoy et al., 1995). Comparison of the
Hom3a region DNA with the sequences in msx-2 which
appear to mediate AER expression (Sumoy et al., 1995),
however, failed to reveal any distinctly conserved se-
quences.
In conclusion, we show in this report that the gene
encoding Fgf4 relies on multiple and distinct enhancer-like
elements to achieve tissue- and stage-specific expression
during embryonic development. While the precise under-
standing of the mechanism regulating Fgf4 expression at
each site will require further work, the identification of
these cis-acting DNA elements and the creation of trans-
genic mice lines which express b-gal in specific develop-
mental stages and tissues should greatly facilitate this
aspect of the investigation. Since the Fgf4 DNA regulatory
elements that we identified appear to function indepen-
dently of each other, it should also be possible to introduce
mutations in one or more of these regulatory elements by
homologous recombination to generate mice which fail to
express FGF4 in specific developmental structures.
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